Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Free Cash Flow (2020 - 2025)

Gain Therapeutics has reported Free Cash Flow over the past 6 years, most recently at -$4.6 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$4.6 million for Q4 2025, down 33.65% from a year ago — trailing twelve months through Dec 2025 was -$18.5 million (up 2.17% YoY), and the annual figure for FY2025 was -$18.5 million, up 2.28%.
  • Free Cash Flow for Q4 2025 was -$4.6 million at Gain Therapeutics, up from -$4.9 million in the prior quarter.
  • Over the last five years, Free Cash Flow for GANX hit a ceiling of -$2.2 million in Q3 2021 and a floor of -$6.1 million in Q3 2024.
  • Median Free Cash Flow over the past 5 years was -$4.1 million (2021), compared with a mean of -$4.2 million.
  • Biggest five-year swings in Free Cash Flow: crashed 663.78% in 2021 and later soared 38.95% in 2024.
  • Gain Therapeutics' Free Cash Flow stood at -$4.2 million in 2021, then rose by 5.86% to -$3.9 million in 2022, then crashed by 44.62% to -$5.7 million in 2023, then soared by 38.95% to -$3.5 million in 2024, then tumbled by 33.65% to -$4.6 million in 2025.
  • The last three reported values for Free Cash Flow were -$4.6 million (Q4 2025), -$4.9 million (Q3 2025), and -$5.1 million (Q2 2025) per Business Quant data.